These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31713130)

  • 81. Early discharge criteria in patients with acute bacterial skin and skin structure infections in a large tertiary-care teaching hospital in Florence, Italy.
    Lagi F; Ottino L; Mantengoli E; Distefano A; Corti G; Farese A; Dannaoui B; Ipponi A; Falai T; Rossolini GM; Bartoloni A; Bartalesi F
    Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1781-1785. PubMed ID: 31222396
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Evaluating the Use of Dalbavancin for Off-Label Indications.
    Taylor K; Williamson J; Luther V; Stone T; Johnson J; Gruss Z; Russ-Friedman C; Ohl C; Beardsley J
    Infect Dis Rep; 2022 Apr; 14(2):266-272. PubMed ID: 35447884
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.
    Lodise TP; Redell M; Armstrong SO; Sulham KA; Corey GR
    Open Forum Infect Dis; 2017; 4(1):ofw274. PubMed ID: 28480266
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study.
    Krsak M; Scherger S; Miller MA; Cobb V; Montague BT; Henao-Martínez AF; Molina KC
    Ther Adv Infect Dis; 2024; 11():20499361231223889. PubMed ID: 38249543
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios.
    Cacopardo B; Cattaneo D; Cortese F; Di Luca M; Falcone M; Marchetti G; Tascini C; Tiseo G; Venditti M
    Expert Rev Anti Infect Ther; 2022 Jul; 20(7):997-1004. PubMed ID: 35353020
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
    Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
    Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Co-ordinated multidisciplinary intervention to reduce time to successful extubation for children on mechanical ventilation: the SANDWICH cluster stepped-wedge RCT.
    Blackwood B; Morris KP; Jordan J; McIlmurray L; Agus A; Boyle R; Clarke M; Easter C; Feltbower RG; Hemming K; Macrae D; McDowell C; Murray M; Parslow R; Peters MJ; Phair G; Tume LN; Walsh TS; McAuley DF
    Health Technol Assess; 2022 Mar; 26(18):1-114. PubMed ID: 35289741
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections.
    Wang Y; Wang J; Wang R; Li Y; Cai Y
    J Glob Antimicrob Resist; 2021 Mar; 24():72-80. PubMed ID: 33279683
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.
    Rappo U; Puttagunta S; Shevchenko V; Shevchenko A; Jandourek A; Gonzalez PL; Suen A; Mas Casullo V; Melnick D; Miceli R; Kovacevic M; De Bock G; Dunne MW
    Open Forum Infect Dis; 2019 Jan; 6(1):ofy331. PubMed ID: 30648126
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
    Huang X; Beresford E; Lodise T; Friedland HD
    Am J Health Syst Pharm; 2013 Jun; 70(12):1057-64. PubMed ID: 23719884
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections.
    Dunne MW; Zhou M; Darpo B
    Int J Antimicrob Agents; 2015 Apr; 45(4):393-8. PubMed ID: 25681068
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
    Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
    Trials; 2022 May; 23(1):407. PubMed ID: 35578360
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Impact of an antimicrobial stewardship program on patients with acute bacterial skin and skin structure infections.
    Pasquale TR; Trienski TL; Olexia DE; Myers JP; Tan MJ; Leung AK; Poblete JE; File TM
    Am J Health Syst Pharm; 2014 Jul; 71(13):1136-9. PubMed ID: 24939504
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Identification of Patient Characteristics Influencing Setting of Care Decisions for Patients With Acute Bacterial Skin and Skin Structure Infections: Results of a Discrete Choice Experiment.
    Lane S; Johnston K; Sulham KA; Syed I; Pollack CV; Holland T; Nathwani D
    Clin Ther; 2016 Mar; 38(3):531-44; quiz 544.e1-9. PubMed ID: 26874786
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
    Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
    Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.
    Cattaneo D; Fusi M; Colaneri M; Fusetti C; Genovese C; Giorgi R; Matone M; Merli S; Petri F; Gori A
    Antibiotics (Basel); 2023 Dec; 13(1):. PubMed ID: 38247579
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Effect of a multifaceted stewardship intervention on antibiotic prescribing and outcomes for acute bacterial skin and skin structure infections.
    Roshdy D; Jaffa R; Pillinger KE; Guffey J; Rozario N; Davidson L; McCurdy L
    Ther Adv Infect Dis; 2018 Nov; 5(6):103-109. PubMed ID: 30430008
    [TBL] [Abstract][Full Text] [Related]  

  • 98. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
    Juul JJ; Mullins CF; Peppard WJ; Huang AM
    Ther Clin Risk Manag; 2016; 12():225-32. PubMed ID: 26937194
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
    Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.
    Saddler K; Zhang J; Sul J; Patel P; Castro-Lainez M; Stevens ML; Kosler S; Lowery E; Sierra-Hoffman M
    PLoS One; 2021; 16(3):e0248129. PubMed ID: 33735185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.